MA27851A1 - Preparation pharmaceutique solide - Google Patents

Preparation pharmaceutique solide

Info

Publication number
MA27851A1
MA27851A1 MA28649A MA28649A MA27851A1 MA 27851 A1 MA27851 A1 MA 27851A1 MA 28649 A MA28649 A MA 28649A MA 28649 A MA28649 A MA 28649A MA 27851 A1 MA27851 A1 MA 27851A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
solid pharmaceutical
coa reductase
containing particles
inhibitor
Prior art date
Application number
MA28649A
Other languages
English (en)
Inventor
Naoru Hamaguchi
Hiroyoshi Koyama
Masafumi Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA27851A1 publication Critical patent/MA27851A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une préparation solide comportant un sensibilisateur à l'insuline et un inhibiteur de l'HMG-CoA réductase sans nuire à la stabilité de ces médicaments, oé ladite préparation comporte des particules contenant un sensibilisateur à l'insuline et des particules contenant un inhibiteur de THMG-CoA réductase. Nombre de lignes : 866
MA28649A 2003-06-06 2005-12-09 Preparation pharmaceutique solide MA27851A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003162241 2003-06-06

Publications (1)

Publication Number Publication Date
MA27851A1 true MA27851A1 (fr) 2006-04-03

Family

ID=33508660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28649A MA27851A1 (fr) 2003-06-06 2005-12-09 Preparation pharmaceutique solide

Country Status (15)

Country Link
US (1) US20060280794A1 (fr)
EP (1) EP1642593A1 (fr)
KR (1) KR20060016787A (fr)
CN (1) CN1802178A (fr)
AU (1) AU2004244889A1 (fr)
BR (1) BRPI0410555A (fr)
CA (1) CA2528164A1 (fr)
IL (1) IL172206A0 (fr)
MA (1) MA27851A1 (fr)
MX (1) MXPA05013147A (fr)
NO (1) NO20060023L (fr)
RU (1) RU2005137865A (fr)
TW (1) TW200510002A (fr)
WO (1) WO2004108161A1 (fr)
ZA (1) ZA200508932B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US7780985B2 (en) * 2005-07-12 2010-08-24 Accu-Break Technologies, Inc. Tablets having a printed separation mark to guide breaking
US7329418B2 (en) * 2004-05-21 2008-02-12 Accu Break Technologies, Inc. Pharmaceutical tablets having height greater than width
US7713547B2 (en) 2004-05-21 2010-05-11 Accu-Break Pharmaceuticals, Inc. Method of administering a partial dose of a segmented pharmaceutical tablet
US7838031B2 (en) 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
AU2005292670B2 (en) * 2004-05-21 2011-02-03 Accu-Break Technologies, Inc. Scored pharmaceutical tablets comprising a plurality of segments
KR100714616B1 (ko) * 2005-06-23 2007-05-07 삼성전기주식회사 지수 함수 발생기 및 이를 이용한 가변 이득 증폭기
CN1331476C (zh) * 2005-07-05 2007-08-15 凌沛学 一种辅酶a舌下含片及其制备方法
EP1948138A4 (fr) * 2005-11-18 2012-07-11 Accu Break Technologies Inc Formes galeniques pharmaceutiques segmentées
RU2426530C2 (ru) 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
US20110086092A1 (en) * 2006-08-08 2011-04-14 Accu-Break Technologies, Inc. Pharmacuetical tablets containing a plurality of active ingredients
WO2008067485A1 (fr) * 2006-11-30 2008-06-05 Accu-Break Technologies, Inc. Formes de dosage osmotique divisibles et leur procédé d'utilisation
EP2100608A4 (fr) * 2006-12-07 2009-12-09 Daiichi Sankyo Co Ltd Procédé de production d'une préparation solide
WO2008091870A2 (fr) * 2007-01-24 2008-07-31 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques comprenant de l'atorvastatine et de l'acide nicotinique
CL2008000684A1 (es) * 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
EP2374007A2 (fr) 2008-12-04 2011-10-12 IKFE GmbH Biomarkers pour l'athérosclérose
EP2376926A1 (fr) 2008-12-11 2011-10-19 IKFE GmbH Biomarqueurs pour réponse aux sensibilisateurs à l'insuline
EP2382467A1 (fr) 2008-12-30 2011-11-02 IKFE GmbH Biomarqueurs de l'activité des tissus adipeux
WO2010079428A2 (fr) 2009-01-07 2010-07-15 Ikfe Gmbh Marqueurs biologiques pour la régulation de l'appétit
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
CN102028671A (zh) * 2010-12-27 2011-04-27 山东淄博新达制药有限公司 盐酸吡格列酮胶囊及其制备方法
PL2665477T3 (pl) * 2011-01-20 2016-05-31 Bionevia Pharmaceuticals Inc Kompozycje epalrestatu lub jego pochodnej o zmodyfikowanym uwalnianiu i sposoby ich stosowania
US9339543B2 (en) 2011-10-12 2016-05-17 Merck Sharp & Dohme Corp. Pharmaceutical compositions that inhibit disproportionation
PE20141189A1 (es) 2011-10-21 2014-09-24 Takeda Pharmaceutical Preparacion de liberacion sostenida
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN108366959A (zh) * 2015-10-09 2018-08-03 科姆博盖股份有限公司 具有体积可调整的内部隔片的胶囊
CN108421045B (zh) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 一种阿托伐他汀钙组合物、制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
JPH05229936A (ja) * 1992-02-19 1993-09-07 Lion Corp 内服用顆粒製剤
WO1995011042A1 (fr) * 1993-10-21 1995-04-27 Hisamitsu Pharmaceutical Co., Inc. Composition administree par voie nasale et preparation contenant celle-ci
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
SE9804314D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
JP2001294537A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd 併用医薬
KR100897890B1 (ko) * 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법

Also Published As

Publication number Publication date
TW200510002A (en) 2005-03-16
KR20060016787A (ko) 2006-02-22
IL172206A0 (en) 2006-04-10
CA2528164A1 (fr) 2004-12-16
RU2005137865A (ru) 2006-06-10
CN1802178A (zh) 2006-07-12
NO20060023L (no) 2006-03-06
ZA200508932B (en) 2007-03-28
EP1642593A1 (fr) 2006-04-05
AU2004244889A1 (en) 2004-12-16
US20060280794A1 (en) 2006-12-14
BRPI0410555A (pt) 2006-06-20
WO2004108161A1 (fr) 2004-12-16
MXPA05013147A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
MA27851A1 (fr) Preparation pharmaceutique solide
BRPI0409068A (pt) composições farmacêuticas para inibidores de protease viral de hepatite c.
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0508125A (pt) formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
MA30975B1 (fr) Formulation parenterale d'anticorps anti-peptide abeta
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
Sica et al. Rhabdomyolysis and satin therapy: relevance to the elderly
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
RS52110B (en) DIPEPTIDIL PEPTIDASE INHIBITORS FOR TREATMENT OF DIABETES
BR0307524A (pt) Composição farmacêutica para inibidores de protease viral de hepatite c
IS7391A (is) ACC hindrar
BR0213355A (pt) composições farmacêuticas
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
Callens et al. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir
Manns et al. Overall safety profile of boceprevir plus peginterferon alfa‐2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
EA200400819A1 (ru) Парентеральная композиция парацетамола
EA200000240A1 (ru) Соединения, препятствующие эффекту раннего превращения лекарственных средств
Kater et al. Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction
Nishida et al. The bioequivalence and effect of food on the pharmacokinetics of a fixed‐dose combination tablet containing rosuvastatin and ezetimibe in healthy Japanese subjects
Fontoura et al. Emerging therapeutic targets in multiple sclerosis
BRPI0410840A (pt) derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
EA200401212A1 (ru) Применение ингибиторов ферментов с активностью аминопептидазы n и/или дипептидилпептидазы iv и фармацевтические композиции на их основе для лечения и профилактики дерматологических заболеваний с себоцитарной гиперпролиферацией и измененными дифференцированными состояниями